Nf Κb P50 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The NF-κB p50 protein is a subunit of the NF-κB transcription factor complex, encoded by the NFKB1 gene. As p105 precursor, it is processed to form the active p50 subunit. NF-κB is a master regulator of inflammatory and immune responses, and chronic activation contributes to neuroinflammation in neurodegenerative diseases.
| Attribute |
Value |
| Protein Name |
NF-κB p50 (Nuclear Factor Kappa-B) |
| Gene |
NFKB1 |
| UniProt ID |
P19838 |
| PDB ID |
1NFK, 2DBF |
| Molecular Weight |
p105: 105 kDa; p50: 50 kDa |
| Subcellular Localization |
Nucleus (active), Cytosol (inactive with IκB) |
| Protein Family |
NF-κB family (REL homology domain) |
- RHD (REL Homology Domain): DNA binding and dimerization
- Ankyrin repeats: Present in p105 (not p50)
- Transactivation domain: Present in p65, absent in p50
NF-κB (p50/p65 heterodimer) regulates:
- Inflammatory Genes: Cytokines (TNF-α, IL-1β, IL-6), chemokines
- Cell Survival: Anti-apoptotic genes (Bcl-2, Bcl-xL, IAPs)
- Immune Response: Innate and adaptive immunity
- Synaptic Plasticity: Required for LTP and memory
- Chronic activation in astrocytes and microglia
- Drives pro-inflammatory cytokine production
- Aβ activates NF-κB pathway
- Activated in substantia nigra microglia
- Contributes to dopaminergic neuron loss
- NF-κB activation in motor neurons and glia
- Contributes to neuroinflammation
| Strategy |
Approach |
Status |
| IKK inhibitors |
Block IκB degradation |
Preclinical |
| Proteasome inhibitors |
Prevent NF-κB activation |
Approved (cancer) |
| Natural compounds |
Curcumin, resveratrol |
Research |
NF-κB p50 plays complex roles in neurodegeneration:
- Alzheimer's Disease: p50-mediated transcription contributes to neuroinflammation in AD brains. However, p50 also has anti-inflammatory properties as a homodimer that represses pro-inflammatory genes.
- Parkinson's Disease: NF-κB activation in microglia contributes to dopaminergic neuron death. p50 deficiency may exacerbate or protect depending on context.
- Amyotrophic Lateral Sclerosis: NF-κB is chronically activated in ALS microglia and astrocytes. p50 balances neuroprotective and neurotoxic microglial responses.
- Huntington's Disease: Mutant huntingtin interacts with NF-κB pathways, affecting neuronal survival and glia-mediated inflammation.
Targeting NF-κB p50 offers therapeutic opportunities:
- Selective Inhibitors: p50-specific inhibitors may modulate neuroinflammation without completely blocking NF-κB function.
- IκB Kinase Modulators: Targeting upstream kinases affects all NF-κB subunits including p50.
- Natural Compounds: Curcumin, resveratrol, and other natural NF-κB inhibitors show preclinical promise.
- Understanding p50 homodimer vs p50/p65 heterodimer functions in the brain
- Developing brain-penetrant NF-κB modulators
- Investigating p50 as a biomarker for neuroinflammation
- Role in microglial polarization
- NFKB1 Knockout Mice: Develop defects in immune cell function and show altered inflammatory responses.
- Conditional KO Models: Neuron-specific deletion reveals cell-type specific roles.
- Transgenic p50 Overexpression: Protects against some forms of brain injury.
The study of Nf Κb P50 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.